Researchers at Oxford and UNC-Chapel Hill, led by Andrew Moon, MD, MPH, and Sidney Barritt, MD, found increased mortality rates among COVID-19 patients with advanced cirrhosis and alcohol-related liver disease.
OXFORD, UK – October 6, 2020 – An international study led by researchers at Oxford University Hospitals NHS Foundation Trust has shown that patients with cirrhosis are at increased risk of dying as a result of COVID-19.
The study, published in the Journal of Hepatology, found that mortality from COVID-19 was particularly high among patients with more advanced cirrhosis – called Childs-Pugh B or C cirrhosis – and those with alcohol-related liver disease.
The study was a collaboration between scientists at the Oxford Liver Unit, based at Oxford’s John Radcliffe Hospital, and colleagues at the University of North Carolina School of Medicine led by Andrew Moon, MD, and Sidney Barritt, MD, of the UNC Department of Medicine. The study was supported by the European Association for the Study of the Liver.
The paper presented data on over 1,300 patients from 29 countries, and it compared COVID-19 outcomes between patients with and without liver disease.
“Our study confirms that severity of liver disease is closely associated with poor outcomes from COVID-19, with cirrhosis patients being at significantly increased risk of death,” said Thomas Marjot, MD, who led the study alongside professor Eleanor Barnes at Oxford University Hospitals. “Given the huge global burden of cirrhosis, with an estimated 112 million people affected, and the resurgence of the virus in many areas of the world these findings have far-reaching implications for how we manage patients with liver disease during the pandemic. This includes the need to consider enhanced protection and social distancing for patients with advanced cirrhosis.”
The study found that mortality among patients with cirrhosis was 32%, compared with 8% in those without. However, the risk of mortality increased in those with more advanced forms of cirrhosis, rising as high as 51% in those in the most severe category. Other risk factors for death included advancing age and alcohol-related liver disease.
The majority of deaths in cirrhosis patients (71%) were from respiratory failure caused by COVID-19. The virus also seemed to cause a deterioration in liver function, with patients developing complications such as ascites or encephalopathy even in the absence of typical respiratory symptoms of COVID-19.
This work follows a recent publication from the same group in The Lancet Gastroenterology and Hepatology, which showed that liver transplant recipients did not appear to be at increased risk of death from the virus.
Andrew Moon, MD, MPH, a fellow in the UNC Department of Medicine, said, “This study nicely compliments our findings in patients with prior liver transplantation. In contrast to the presence of advanced cirrhosis, having a liver transplantation was not associated with increased risk of death from COVID-19. This suggests that we should aim to continue liver transplant services during the pandemic wherever possible.”
Professor Thomas Berg, EASL Vice-Secretary General and Head of the Division of Hepatology at Leipzig University Medical Centre in Germany, said: “The findings from this large registry study are very relevant to clinicians and patients worldwide, as we continue to optimise liver disease management during the pandemic. These results are timely and reinforce the recommendations made in the joint Position Papers by EASL and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) published in JHEP Reports, which offer guidance on how to approach patients with different types and stages of liver disease.”
Roy Probert, Oxford University, 07341 115585
Mark Derewicz, UNC School of Medicine, 919-923-0959